DK2877494T3 - PTPRS og proteoglycaner i autoimmun sygdom - Google Patents

PTPRS og proteoglycaner i autoimmun sygdom Download PDF

Info

Publication number
DK2877494T3
DK2877494T3 DK13823022.2T DK13823022T DK2877494T3 DK 2877494 T3 DK2877494 T3 DK 2877494T3 DK 13823022 T DK13823022 T DK 13823022T DK 2877494 T3 DK2877494 T3 DK 2877494T3
Authority
DK
Denmark
Prior art keywords
ptprs
proteoglycans
autoimmune disease
autoimmune
disease
Prior art date
Application number
DK13823022.2T
Other languages
English (en)
Inventor
Nunzio Bottini
Stephanie Stanford
Original Assignee
La Jolla Inst Allergy & Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by La Jolla Inst Allergy & Immunology filed Critical La Jolla Inst Allergy & Immunology
Application granted granted Critical
Publication of DK2877494T3 publication Critical patent/DK2877494T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK13823022.2T 2012-07-23 2013-07-23 PTPRS og proteoglycaner i autoimmun sygdom DK2877494T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261674853P 2012-07-23 2012-07-23
US201261675036P 2012-07-24 2012-07-24
US201361832688P 2013-06-07 2013-06-07
PCT/US2013/051723 WO2014018554A1 (en) 2012-07-23 2013-07-23 Ptprs and proteoglycans in autoimmune disease

Publications (1)

Publication Number Publication Date
DK2877494T3 true DK2877494T3 (da) 2020-09-21

Family

ID=49997782

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13823022.2T DK2877494T3 (da) 2012-07-23 2013-07-23 PTPRS og proteoglycaner i autoimmun sygdom

Country Status (5)

Country Link
US (2) US20150175979A1 (da)
EP (1) EP2877494B1 (da)
DK (1) DK2877494T3 (da)
ES (1) ES2817897T3 (da)
WO (1) WO2014018554A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
WO2016123163A2 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
EP3454885A4 (en) * 2016-05-12 2019-12-25 Ohio State Innovation Foundation PEPTIDES AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
US20200132673A1 (en) * 2017-03-24 2020-04-30 The Regents Of The University Of California Proteoglycan irregularities in abnormal fibroblasts and therapies based therefrom
US20210393740A1 (en) * 2018-09-19 2021-12-23 La Jolla Institute For Immunology Ptprs and proteoglycans in rheumatoid arthritis
US20250082734A1 (en) * 2021-07-30 2025-03-13 The Regents Of The University Of California Ptprs in autoimmunity

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US5830645A (en) 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
JP2002531466A (ja) 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体
EP2314700A1 (en) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
JP2004532616A (ja) 2000-12-28 2004-10-28 ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド 二本鎖ｒｎａ仲介遺伝子抑制
JP2009510102A (ja) * 2005-09-29 2009-03-12 ヴァイラル ロジック システムズ テクノロジー コーポレーション 免疫調節組成物およびその使用
EP2531859A4 (en) * 2010-02-02 2013-07-31 Jolla Inst Allergy Immunolog Compositions and methods of modulating receptor protein tyrosine phosphatases
EP2702412B1 (en) * 2011-04-28 2017-07-26 SBI Biotech Co., Ltd. Anti-human receptor-type protein tyrosine phosphatase antibody

Also Published As

Publication number Publication date
US20150175979A1 (en) 2015-06-25
WO2014018554A1 (en) 2014-01-30
US20220325261A1 (en) 2022-10-13
ES2817897T3 (es) 2021-04-08
EP2877494A4 (en) 2016-04-20
EP2877494B1 (en) 2020-07-15
EP2877494A1 (en) 2015-06-03

Similar Documents

Publication Publication Date Title
NL350119I2 (nl) Mefentrifluconazool en prothioconazool
IL269045A (en) Aptamers and uses thereof
DK2855736T3 (da) Elektrolysator og energisystem
DK2850202T3 (da) Fremgangsmåder og grupper
DK2838596T3 (da) Intermitterende katetersamling
DK3470086T3 (da) Pyrrolobenzodiazepiner og konjugater deraf
DK2844282T3 (da) Prostata-associerede antigener og vaccine-baserede immunterapiregimener
EP2870505A4 (en) TRANSPARENT GLOSS AND GLOSS PROTECTION STRUCTURES
DK2815483T3 (da) Flerrumsatterioplader
BR302013000588S1 (pt) Configuração aplicada em instrumento médico
IL236275A0 (en) Structures and packing methods using an external cellular matrix
EP2872036A4 (en) IN VIVO BIOSENSOR
EP2911305A4 (en) MULTIPLEXER
EP2433335A4 (en) Connector
BR112012029414A2 (pt) arquiteturas ordenadas em polímeros acrílicos
EP2701730A4 (en) MFG-E8 AND USES THEREOF
EP2613409A4 (en) Connector
BR302013001848S1 (pt) Configuração aplicada em instrumento médico
FR3015775B1 (fr) Butee de cosse de batterie et unite de cosse de batterie
BR302012006078S1 (pt) Configuração aplicada em instrumento médico
BR302013000213S1 (pt) Configuração aplicada em instrumento médico
DK2943460T3 (da) 6-chlor-3-(phenyl-d5)-inden-1-on og anvendelse deraf
DK2877494T3 (da) PTPRS og proteoglycaner i autoimmun sygdom
HRP20180685T1 (hr) Antitijelo protiv humanog dlk-1 koje posjeduje protutumorsko djelovanje in vivo
EP2584655A4 (en) CONNECTOR